Abstract
Pharmacokinetic studies of adriamycin performed on patients with sarcomas and other tumors have revealed a prolonged plasma half life for the drug and its metabolites. The intermittent single high dosage schedule based upon this pharmacokinetic data has been at least as successful as any other dosage schedule and has substantially reduced the incidence of mucositis, a major manifestation of drug toxicity. Because of low urinary excretion, renal insufficiency should not be expected to increase adriamycin toxicity when the drug is given in full doses. On the other hand, because of the importance of biliary excretion in the pharmacodynamics of adriamycin, major dosage reductions are necessary to prevent life threatening toxic reactions in patients with severe liver disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 271-273 |
| Number of pages | 3 |
| Journal | CANCER CHEMOTHER.REP. |
| Volume | 58 |
| Issue number | 2 |
| State | Published - 1974 |
ASJC Scopus subject areas
- General Medicine